Data completeness
4/8 — Partial
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KLOXXADO is a naloxone hydrochloride nasal spray formulation approved by the FDA in April 2021 for the emergency treatment of opioid overdose. Naloxone is an opioid antagonist that rapidly reverses the effects of opioid overdose by binding to opioid receptors and blocking opioid effects. The nasal spray route provides a non-invasive, easy-to-administer alternative to injectable formulations.
$0.312MPart D
Peak8.2 years to LOEProduct is in peak lifecycle stage with stable Part D utilization; brand team focused on market consolidation and market access expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on KLOXXADO offers career opportunities in a peak-lifecycle, well-protected product with a clear commercial mission in the high-priority opioid crisis market. Positions emphasize market penetration, healthcare provider education, and payer negotiations rather than early-stage development or innovation.
Brand ManagerMedical Science Liaison
Worked on KLOXXADO at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.